SCHEMBL1265031

SCHEMBL1265031

CC(C)(c1ccccc1)c1cc(O)c2c(-c3cccs3)coc2n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
RPS6KB2 Q9UBS0 1/20 0.35
TMIGD3 P0DMS9 2/20 0.34
ADORA2A P29274 2/20 0.34
ADORA1 P30542 2/20 0.34
GPR35 Q9HC97 1/20 0.34
KAT8 Q9H7Z6 1/20 0.33
BAZ2B Q9UIF8 1/20 0.32
BAZ2A Q9UIF9 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
ATM Q13315 1/20 0.32
SMPD3 Q9NY59 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1265703 0.83 CNR1 (0.39) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL1193324 0.82 MAPT (0.35) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL1234703 0.79 CNR1 (0.39) MAPTALDH1A1HPGDTMIGD3ADORA2A
SCHEMBL1265853 0.78 MEN1 (0.33) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL12895241 0.78 CNR1 (0.53) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL1235880 0.78 CNR2 (0.37) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL1193185 0.71 MAPT (0.36) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL1236270 0.70 CNR1 (0.48) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL1193053 0.65 ALDH1A1 (0.33) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL1236041 0.64 CNR1 (0.33) MAPTALDH1A1HPGDTMIGD3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US claimed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US claimed
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US disclosed
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US disclosed
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US disclosed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US disclosed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US disclosed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US disclosed
WO-2011022692-A2 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) 2011-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE CNR1, CNR2, FAAH MAPT 4411/4885ALDH1A1 1175/4885KDM4E 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.